ALXO (ALX Oncology Holdings Inc. Common Stock) Stock Analysis - News
ALX Oncology Holdings Inc. Common Stock (ALXO) is a publicly traded Healthcare sector company. As of May 20, 2026, ALXO trades at $1.96 with a market cap of $269.13M and a P/E ratio of -1.03. ALXO moved +1.79% today. Year to date, ALXO is +77.68%; over the trailing twelve months it is +364.09%. Its 52-week range spans $0.40 to $2.66. Analyst consensus is strong buy with an average price target of $4.75. Rallies surfaces ALXO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in ALXO news today?
ALX Oncology Posts 60% Response Rate in HER2 Trial, Secures $150M: Data show evorpacept plus zanidatamab achieved a 60% confirmed objective response rate and 8.3-month median PFS in centrally confirmed HER2-positive patients, with all five high CD47 expressors responding and a 22.1-month median PFS; ASPEN-09-Breast Phase 2 trial remains on track for mid-2027 topline. The company raised $150 million gross by selling 76,979,112 shares at $1.57 and 18,574,120 pre-funded warrants at $1.569, strengthening its balance sheet for ongoing studies.
ALX Oncology Posts 60% Response Rate in HER2 Trial, Secures $150M: Data show evorpacept plus zanidatamab achieved a 60% confirmed objective response rate and 8.3-month median PFS in centrally confirmed HER2-positive patients, with all five high CD47 expressors responding and a 22.1-month median PFS; ASPEN-09-Breast Phase 2 trial remains on track for mid-2027 topline. The company raised $150 million gross by selling 76,979,112 shares at $1.57 and 18,574,120 pre-funded warrants at $1.569, strengthening its balance sheet for ongoing studies.
Does Rallies summarize ALXO news?
Yes. Rallies summarizes ALXO news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is ALXO research on Rallies investment advice?
No. Rallies provides research, data, and educational context for ALXO. It does not provide personalized investment advice.
